Corsens® is a platform technology that measures, displays and reports electromagnetic fluctuations generated by the activity of the heart.
Creavos first product to market, Corsens®, will enable healthcare professionals to use the device as an aid to rapidly and accurately rule out patients attending the emergency department with symptoms consistent with those of acute coronary syndrome.
Corsens® an aid to rule out A majority of patients presenting to emergency departments with chest pain do not get diagnosed with acute coronary syndrome2. However, most will still follow the extensive chest pain pathway – increasing pressure on already strained clinical resources. With Corsens®, healthcare professionals can utilise the MCG results as an aid to rule out active ischaemia in patients presenting with symptoms consistent with those of acute coronary syndrome and direct them to the most appropriate care pathway. This is achieved by detecting distortions in the hearts magnetic field caused by the presence of ischaemic (lacking oxygen) or necrotic (dead) cells which can be clearly observed in the resulting MCG field map and trace score.
2 Backus et al. 2011; Rohacek et al. 2012; Six et al. 2012; Backus et al. 2013
A vision to transform cardiology We believe our technology has the power to transform the way that heart disease is identified and subsequently treated. Through our ground breaking MCG technology, we aim to reduce the economic burden on healthcare systems worldwide.